Stem Cell Clinic

JARID2 and AEBP2 regulate PRC2 in the presence of H2AK119ub1 and other histone modifications – Science Magazine

By adminJanuary 23, 2021Embryonic Stem Cells

Cryo-EM uncovers polycomb interactions

Polycomb family enzymes include the chromatin modifiers PRC1 and PRC2, which are involved in gene repression. Although the catalytic functions of these complexes are well known, their functional relationship is not. Kasinath et al. used cryoelectron microscopy (cryo-EM) to visualize the interactions between nucleosomes containing ubiquitinated histone H2A, the product of PRC1, and the PRC2-activating cofactors JARID2 and AEBP2, providing the molecular basis for PRC1-dependent recruitment of PRC2. They also show that JARID2 and AEBP2 partially overcome the inhibitory effect of PRC2 by two trimethyl lysine transcription marks on histones. This work suggests that PRC2 regulation involves an intricate interplay between PRC2 cofactors and histone posttranslational modifications.

Science, this issue p. eabc3393

Histone modification activity of the polycomb repressive complexes 1 and 2 (PRC1 and PRC2) is critical for the establishment and maintenance of gene expression patterns and, thus, to the maintenance of cell identity. Distinct classes of cofactor proteins are known to regulate the functional activity and interplay of these two complexes, but we presently lack a comprehensive, mechanistic understanding of this process. Furthermore, PRC2 cofactors like AEBP2 and JARID2 also play a role in mediating the cross-talk between different histone posttranslational modifications and PRC2 recruitment and activitya function that is important for the regulated control of gene expression.

PRC1 is an E3 ubiquitin ligase responsible for the monoubiquitination of histone H2A (H2AK119ub1), a histone mark recognized by PRC2 and linked to its genomic recruitment. We used cryoelectron microscopy (cryo-EM) and biochemical activity assays to probe the role played by PRC2 cofactors JARID2 and AEBP2 in the recognition of H2AK119ub1 and the regulation of PRC2 activity. We extended our cryo-EM and biochemical activity analysis to examine the possible role played by JARID2 and AEBP2 in the cross-talk between the histone H3K4me3, H3K36me3 modifications linked to transcriptionally active regions, and PRC2 activity.

We find that JARID2 recognizes both the ubiquitin moiety in H2AK119ub1 and the conserved histone H2A-H2B acidic patch. We also observe that the tandem zinc fingers of AEBP2 interact with ubiquitin and the histone H2A-H2B surface on the other side of the nucleosome. Biochemical assays show a secondary activation of PRC2 by JARID2 and AEBP2 on H2AK119ub1-containing nucleosomes besides the primary EED-mediated allosteric activation of PRC2 by methylated JARID2. Furthermore, we also find that the joint presence of JARID2 and AEBP2 partially reduces the inhibition of PRC2 methyltransferase activity by the transcriptionally active histone posttranslational modifications H3K4me3 and H3K36me3. Cryo-EM visualization of PRC2 that contains JARID2 and AEBP2 interacting with a H3K4me3-containing nucleosome shows the coexistence of states in which the histone H3 tail is either absent or engaged and reaching the catalytic site in PRC2, which provides a physical basis for the partial activity of the complex on H3K4me3-containing nucleosomes.

Our studies indicate that cofactors JARID2 and AEBP2 play a crucial role in both the recruitment and activation of PRC2 through their recognition of H2AK119ub1, which is generated by PRC1. Additionally, our work suggests that JARID2 and AEBP2 are likely to play a key role in regulating PRC2 activity on genomic regions with active transcription marks. The examination of the genomic distribution in embryonic stem cells of PRC2 core proteins together with JARID2 and AEBP2 will be important to further define their role in the tight regulation of PRC2 activity.

Although core PRC2 is a weak enzyme, it is allosterically activated by JARID2 and AEBP2. The presence of monoubiquitinated histone H2A, the product of PRC1 activity, is recognized by both JARID2 and AEBP2 through interactions that likely mediate recruitment of PRC2 to polycomb sites in the genome and further activate the methyltransferase activity of PRC2 on K27 of histone H3.

Polycomb repressive complexes 1 and 2 (PRC1 and PRC2) cooperate to determine cell identity by epigenetic gene expression regulation. However, the mechanism of PRC2 recruitment by means of recognition of PRC1-mediated H2AK119ub1 remains poorly understood. Our PRC2 cryoelectron microscopy structure with cofactors JARID2 and AEBP2 bound to a H2AK119ub1-containing nucleosome reveals a bridge helix in EZH2 that connects the SET domain, H3 tail, and nucleosomal DNA. JARID2 and AEBP2 each interact with one ubiquitin and the H2A-H2B surface. JARID2 stimulates PRC2 through interactions with both the polycomb protein EED and the H2AK119-ubiquitin, whereas AEBP2 has an additional scaffolding role. The presence of these cofactors partially overcomes the inhibitory effect that H3K4me3 and H3K36me3 exert on core PRC2 (in the absence of cofactors). Our results support a key role for JARID2 and AEBP2 in the cross-talk between histone modifications and PRC2 activity.

Doctor: COVID-19 cases will continue to slowly go down, but were not out of the woods – Yahoo Money

By adminJanuary 23, 2021Stem Cell Doctors

The Daily Beast

Justin Tallis/GettyAs vaccine rollouts ramp upor in some cases, stumble aheadin countries across the world, the SARS-CoV-2 strain has rolled out some new features of its own, primarily in the form of rapid genetic mutations. Some evidence indicates variants of recent months have made the virus more infectious, or in one case, possibly more deadly.Virus variants are inevitable and often benign. The new coronavirus has likely mutated countless times without attracting the attention of epidemiologists. But new strains identified in the U.K., South Africa, Brazil, and California have given some infectious disease experts pause.Several studies indicate that the strain known as the B117 variant, prevalent in the U.K., may be as much as 70 percent more transmissible than the original virus. Two analyses in California suggested that a new strain on the West Coast, called B.1.426, made up a quarter of the infections they examined. As the news whipsaws between infection spikes and inoculation efforts, it can seem like the world has entered a race between variant and vaccine.Is the South African COVID-19 Mutation a Vaccine Killer?The change through mutation is quite rapid, said Dr. Irwin Redlener, pediatric physician and disaster preparedness adviser to New York City Mayor Bill de Blasio. We dont know where its going. This is the reality, that we dont know what to expect. The thing that were more worried about is that it could mutate to become resistant to the vaccines or partially resistant to the vaccines. That would be horrendous. We could make amendments to the vaccine, but it would slow everything down.Overall, the arrival of new, threatening strains should not change the average persons behavior, three epidemiologists and public health advisers told the Daily Beast. In terms of vaccines and mitigation, this doesnt change the mitigation strategies because we know the mitigation works, said Dr. Arnold Monto, University of Michigan epidemiologist and professor of Public Health. But it just means that we have to be all the more serious about following these kinds of rules.I think primarily this reinforces the urgency of every aspect of the pandemic response, echoed Dr. Joshua Sharfstein, vice dean at the Johns Hopkins Bloomberg School of Public Health. Not just vaccination, but also testing contact tracing, precaution taking, and general vigilance it will take much more than vaccinations, because we dont have enough vaccines overall in the short term.The U.K. StrainHealth officials in the U.K. first announced detection of a new strain in mid-Decemberjust one week after it became the first country in the world to start administering a vaccine. In a press conference, National Health Secretary Matt Hancock revealed that the new mutation had been observed in more than 1,000 patients there, prompting a new wave of strict lockdowns across the country. The strain was thought to date back to mid-September. By late December, its spread correlated with a massive uptick in the number of COVID-19 infections throughout the county.The phrase more infectious can be misleading, said Monto. Data on the new strain does not tell us, for example, that someone exposed to it will become infected faster than someone exposed to the old strain under identical conditions. It refers specifically to the rate at which the viruses reproduce.Lets look at this in terms of what we know, said Monto. What we know is that this virus replicates better. In an individual, it takes less of this virus to cause an infection. How do we know this? We dont know about this in terms of people in a room and how many get infected with one variant versus the other. But what is very clear is that this virus is more efficient and has taken over versus the old virus. That tells us that it has some kind of an advantage in reproducing.Britains Mutant Coronavirus Strain Has Swamped the Nation, but a Worse Variant Has Already ArrivedOn Friday, British Prime Minister Boris Johnson announced in a press conference that the dominant variant there could be as much as 30 percent more deadly than the original. The conclusions came from a paper published by the New and Emerging Virus Threats Advisory Groupa study that was, Monto pointed out, based on a very small number of patients in just a handful of settings.Lots of other things could be related to an increase in mortality, he said, including when you have, as they do in the U.K., greater numbers of people under care. Its based on small numbers, so we really cant say anything right now. We cant speculate.It was a pronouncement that he made, Redlener said of Johnson raising the alarm. There wasnt really much evidence to go on. But he drew a conclusion and went public with it... For now, Ill say Boris Johnson should have held his statement until there was more evidence.The South Africa StrainNot long after the U.K. strain was first announced, a variant called B.1.351 emerged in South Africa. The new strain shared some mutations with its British predecessor, according to the CDC. It also seemed to have a higher rate of transmission. Most concerning about the South African strain, however, was a new mutation in its genetic code that some experts feared could reduce the efficacy of COVID-19 vaccines. Some preliminary studiesfew of them peer-reviewedfound that the mutation E484K in the South African variant limited the effectiveness of antibodies by up to 50 percent.Its definitely a concern, Redlener said, referencing a report on the studies from NBCs Richard Engel. Its a concern because a legitimate scientist mentioned it. What we dont know is how reliable his studies were that drove him to that conclusion.Monto found the conclusions less alarming, noting that the studies drew from a small body of research and very few real world cases. The bottom line is that they are trying to see in a lab if the blood from vaccines neutralize the variants as well as they do the original virus, said Dr. Monto. It looks like they are and to date now there are several papers. One says their test is good. Another says its not quite as good, but still okay.Other StrainsAnother new variant was detected in Japan among four travelers from Brazil, according to the CDC. While relatively less is known about the Brazilian variant, Reuters reported Friday that the new strain accounted for nearly half of the new infections in Manaus, the largest city in the Brazilian state of Amazonas.Last summer, a strain of SARS-CoV-2 emerged in Denmark in association with the countrys mink farming industry, according to the WHO. The country killed 17 million minks to prevent the virus from spreading to humans.Worried About Virus Mutations? Theres a Solution.In California, scientists found a new variant in late December, not long after the state underwent its deadliest surge of the pandemic. According to the Los Angeles Times, two research groups observed the new form while looking for evidence that the U.K. strain had traveled west. Also highly transmissible, it now appears to be the fastest-growing variant in the state. In spite of the discovery, local officials and media have largely placed blame on residents, whom they claim have stopped adhering to lockdown guidelines.Its a very complicated questionwhat is causing an outbreak in a particular place, Redlener said. A lot has to do with basic compliance. But on top of that there may be some other strains there that just havent been identified. Were operating in the dark on a lot of stuff. Its a lot of guesswork and speculation. We just have to keep searching.Read more at The Daily Beast.Get our top stories in your inbox every day. Sign up now!Daily Beast Membership: Beast Inside goes deeper on the stories that matter to you. Learn more.

Excerpt from:
Doctor: COVID-19 cases will continue to slowly go down, but were not out of the woods - Yahoo Money

Global Precision Medicine Market With COVID 19 Impact Analysis| Leading Players In-depth Analysis Research Report Foresight to 2027 – KSU | The…

By adminJanuary 23, 2021Stem Cell Doctors

Databridgemarketresearch.com Present Global Precision Medicine Market Industry Trends and Forecast to 2027 new report to its research database. This Global Precision Medicine Market report is structured with the thorough market analysis carried out by a team of industry experts, dynamic analysts, skilful forecasters and well-informed researchers. And not to mention, the report is amazingly characterized by using several charts, graphs and tables depending on the extent of data and information involved. Businesses can achieve complete knowhow of general market conditions and tendencies with the information and data covered in this report. What is more, influencing factors such as market drivers, market restraints and competitive analysis is studied with the SWOT analysis which is the most established tool when it comes to generate market research report.

Global Precision Medicine Market report comprises of all the crucial parameters mentioned above hence it can be used for your business. Furthermore, systemic company profiles covered in this report also explains what recent developments, product launches, joint ventures, mergers and acquisitions are taking place by the numerous key players and brands in the market. This report also endows with company profiles and contact information of the key market players in the key manufacturers section. The report is provided with the transparent research studies which have taken place by a team work of experts in their own domain.

Global Precision Medicine Market to grow with a substantial CAGR in the forecast period of 2019-2026. Growing prevalence of cancer worldwide and accelerating demand of novel therapies to prevent of cancer related disorders are the key factors for lucrative growth of market

Key Market Players:

Few of the major competitors currently working in the global precision medicine market are Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG, PERSONALIS INC, GENOCEA BIOSCIENCES, INC., F. Hoffmann-La Roche Ltd, CureVac AG, CELLDEX THERAPEUTICS, BIONTECH SE, Advaxis, Inc, GlaxoSmithKline plc, Bioven International Sdn Bhd, Agenus Inc., Immatics Biotechnologies GmbH, Immunovative Therapies, Bristol-Myers Squibb Company, Gritstone Oncology, NantKwest, Inc among others.

Download Free PDF Sample Copy of Report@ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-precision-medicine-market

Global Precision Medicine Market By Application (Diagnostics, Therapeutics and Others), Technologies (Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics and Others), Indication (Oncology, Central Nervous System (CNS) Disorders, Immunology Disorders, Respiratory Disorders, Others), Drugs (Alectinib, Osimertinib, Mepolizumab,Aripiprazole lauroxil and Others), Route of Administration (Oral,Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Competitive Analysis:

The precision medicine market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of mass spectrometry market for global, Europe, North America, Asia Pacific and South America.

Market Drivers

Market Restraints

Talk to The Author of Report @ http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-precision-medicine-market

Market Definition:

Precision medicines is also known as personalized medicines is an innovative approach to the patient care for disease treatment, diagnosis and prevention base on the persons individual genes. It allows doctors or physicians to select treatment option based on the patients genetic understanding of their disease.

According to the data published in PerMedCoalition, it was estimated that the USFDA has approved 25 novels personalized medicines in the year of 2018. These growing approvals annually by the regulatory authorities and rise in oncology and CNS disorders worldwide are the key factors for market growth.

Grab Your Report at an Impressive 30% Discount! Please click Here@https://www.databridgemarketresearch.com/request-a-discount/global-precision-medicine-market

Key Developments in the Market:

Competitive Analysis:

Global precision medicine market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global precision medicine market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Segmentation:

By technology:- big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others.

By application:- oncology, hematology, infectious diseases, cardiology, neurology, endocrinology, pulmonary diseases, ophthalmology, metabolic diseases, pharmagenomics, and others.

On the basis of end-users:- pharmaceuticals, biotechnology, diagnostic companies, laboratories, and healthcare it specialist.

On the basis of geography:- North America & South America, Europe, Asia-Pacific, and Middle East & Africa. U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others.

In 2017, North America is expected to dominate the market.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:Corporatesales@databridgemarketresearch.com

See the original post here:
Global Precision Medicine Market With COVID 19 Impact Analysis| Leading Players In-depth Analysis Research Report Foresight to 2027 - KSU | The...

Groundbreaking Trial Shows Umbilical-Cord Derived Mesenchymal Stem Cell Infusions Save Lives of Sickest COVID-19 Patients – HospiMedica

By adminJanuary 22, 2021Stem Cell Treatment

Image: Camillo Ricordi, M.D., director of the Diabetes Research Institute (DRI) and Cell Transplant Center at the University of Miami Miller School of Medicine (Photo courtesy of University of Miami Health System)

Researchers at the University of Miami Miller School of Medicine (Miami, FL, USA) who led the study believe that treating COVID-19 with mesenchymal stem cells makes sense. Mesenchymal cells not only help correct immune and inflammatory responses that go awry, they also have antimicrobial activity and have been shown to promote tissue regeneration. When given intravenously, mesenchymal stem cells migrate naturally to the lungs. Thats where therapy is needed in COVID-19 patients with acute respiratory distress syndrome, a dangerous complication associated with severe inflammation and fluid buildup in the lungs.

In the new study, 24 hospitalized COVID-19 patients who had developed severe acute respiratory distress syndrome each received two infusions given days apart of either mesenchymal stem cells or a placebo. Researchers found the treatment was safe, with no infusion-related serious adverse events. Patient survival at one month was 91% in the stem cell treated group versus 42% in the control group. Among patients younger than 85 years old, 100% of those treated with mesenchymal stem cells survived at one month.

The researchers also found that recovery was faster among those in the treatment arm. More than half of patients treated with mesenchymal stem cell infusions recovered and went home from the hospital within two weeks after the last treatment. More than 80% of the treatment group recovered by day 30, versus less than 37% in the control group. The next step is to study use of the stem cells in COVID-19 patients who have not yet become severely ill but are at risk of having to be intubated, to determine if the infusions prevent disease progression.

The umbilical cord contains progenitor stem cells, or mesenchymal stem cells, that can be expanded and provide therapeutic doses for over 10,000 patients from a single umbilical cord, said the studys senior author, Camillo Ricordi, M.D., director of the Diabetes Research Institute (DRI) and Cell Transplant Center at the University of Miami Miller School of Medicine. Its a unique resource of cells that are under investigation for their possible use in cell therapy applications, anytime you have to modulate immune response or inflammatory response.

Our results confirm the powerful anti-inflammatory, immunomodulatory effect of UC-MSC (umbilical-cord derived mesenchymal stem cells). These cells have clearly inhibited the cytokine storm, a hallmark of severe COVID-19, said Giacomo Lanzoni, Ph.D., lead author of the paper and assistant research professor at the Diabetes Research Institute. The results are critically important not only for COVID-19 but also for other diseases characterized by aberrant and hyperinflammatory immune responses, such as autoimmune type 1 diabetes.

Related Links:University of Miami Miller School of Medicine

Link:
Groundbreaking Trial Shows Umbilical-Cord Derived Mesenchymal Stem Cell Infusions Save Lives of Sickest COVID-19 Patients - HospiMedica

Autologous stem cell transplantation versus bortezomib for the first line treatment of systemic light chain amyloidosis in the UK – DocWire News

By adminJanuary 22, 2021Stem Cell Treatment

This article was originally published here

Eur J Haematol. 2021 Jan 18. doi: 10.1111/ejh.13582. Online ahead of print.

ABSTRACT

OBJECTIVES: The benefit of autologous stem cell transplantation (ASCT) in the treatment of light chain (AL) amyloidosis requires re-evaluation in the modern era. This retrospective case-matched study compares ASCT to bortezomib for the treatment of patients with AL amyloidosis.

METHODS: Newly diagnosed patients with AL amyloidosis treated with ASCT or bortezomib between 2001-2018 were identified. Patients were excluded if the time from diagnosis to treatment exceeded 12 months. Patients were matched on a 1:1 basis, using a propensity matched scoring approach.

RESULTS: A total of 136 propensity-score matched patients were included (ASCT n= 68, bortezomib n=68). There was no significant difference in overall survival at two years (p=0.908, HR: 0.95, CI:0.41-2.20). For ASCT vs. bortezomib: overall haematological response rate at six months was 90.6% vs. 92.5%; organ response at 12 months: cardiac (70.0% vs. 54%, p>0.999), renal (74% vs.24%, p=0.463)) liver (21% vs. 22%, p=0.048); median progression free survival (50 vs. 42 months p=0.058, HR:0.61, CI:0.37-1.02) and time to next treatment (68 vs. 45 months, p=0.145, HR:0.61, CI:0.31-1.19). More patients required treatment in the bortezomib group compared to ASCT group at 24 months (41 vs. 23, Chi squared p=0.004) and 48 months (57 vs 41, Chi squared p= 0.004).

CONCLUSIONS: This small retrospective study suggests that there is no clear survival advantage of ASCT over bortezomib therapy. A prospective randomised controlled trial evaluating ASCT in AL amyloidosis is critically needed.

PMID:33460466 | DOI:10.1111/ejh.13582

Massive Growth in Canine Stem Cell Therapy Market Set to Witness Huge Growth by 2027| VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana…

By adminJanuary 22, 2021Stem Cell Treatment

Canine Stem Cell Therapy Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

The global Canine Stem Cell Therapy Market size is expected to Expand at Significant CAGR of +4% during forecast period (2021-2027).

The non-invasive stem cell obtaining procedure, augmented possibility of accomplishing high quality cells, and lower price of therapy coupled with high success rate of positive outcomes have collectively made allogeneic stem cell therapy a preference for veterinary physicians. Moreover, allogeneic stem cell therapy is 100% safe, which further supports its demand on a global level.

Get Sample Copy of this report with latest Industry Trend and COVID-19 Impact @:

https://www.a2zmarketresearch.com/sample?reportId=21262

Some of the Top companies Influencing in this Market includes:

VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos.

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Canine Stem Cell Therapy market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Canine Stem Cell Therapy markets trajectory between forecast periods.

Global Canine Stem Cell Therapy Market Segmentation:

Market Segmentation: By Type

Market Segmentation: By Application

Global Canine Stem Cell Therapy Market research report offers:

Get Up to 30% Discount on the first purchase of this report @:

https://www.a2zmarketresearch.com/discount?reportId=21262

Regions Covered in the Global Canine Stem Cell Therapy Market Report 2020: The Middle East and Africa(GCC Countries and Egypt) North America(the United States, Mexico, and Canada) South America(Brazil etc.) Europe(Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The cost analysis of the Global Canine Stem Cell Therapy Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

Key questions answered in the report include:

Table of Content (TOC)

Global Canine Stem Cell Therapy Market Report 2021 Growth, Trend and Forecast to 2027

Chapter 1 Canine Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Canine Stem Cell Therapy Industry

Chapter 3 Global Canine Stem Cell Therapy Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region (2014-2020)

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions (2014-2020)

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Canine Stem Cell Therapy Market Forecast (2020-2026)

Chapter 13 Appendix

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=21262

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

sales@a2zmarketresearch.com

+1 775 237 4147

Here is the original post:
Massive Growth in Canine Stem Cell Therapy Market Set to Witness Huge Growth by 2027| VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana...

Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada – InvestorIntel

By adminJanuary 22, 2021Stem Cell Treatment

January 22, 2021 (Source) Hemostemix Inc. (TSXV: HEM) (OTC: HMTXD) (Hemostemix or the Company) is pleased to announce it has signed the Building Relationships Entrepreneurs & Dealmakers (BREAD) contract with the Department of Foreign Affairs, Trade and Development. An initiative to assist high-potential, biotech focused Canadian Small and Medium Enterprise (SMEs), the program is designed to accelerate the growth of Hemostemix and other Canadian biotechnology companies.

We are actively working with the Trade Commissioner Service of CANADA in the USA, Japan and South Korea to source qualified partners to go to market with, stated Thomas Smeenk, CEO. The BREAD agreement marks our Companys starting point to out-license ACP-01, and it generates our sponsorship into BioCom.

ABOUT THE TRADE COMMISSIONER SERVICE OF CANADA

The Trade Commissioner Service (TCS) plays an active role in helping Canadian companies achieve their goals of growth into international markets. Its services focus on helping companies prepare for international markets, assessing market potential, finding qualified contacts and partners and resolving problems.

ABOUT HEMOSTEMIX

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up, which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visitwww.hemostemix.com.

For further information, please contact:

Thomas Smeenk, President, CEO & Co-Founder Suite 1150, 707 7thAvenue S.W., Calgary, Alberta T2P 3H6 Phone: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward-Looking Information: This news release contains forward-looking information within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the commercialization of ACP-01. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemixs current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its common shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the Litigation); the results of ACP-01 research, trials studies and analysis, including the midpoint analysis, being equivalent to or better than previous research, trials or studies as well as managements expectations of anticipated results; Hemostemixs general and administrative costs remaining constant; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemixs services and products; competition and Hemostemixs competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemixs operations including any research, trials or studies, and the Litigation. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete its current CLI clinical trial, complete a satisfactory futility analysis and the results of such and future clinical trials; litigation and potential litigation that Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemixs markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemixs ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemixs disclosure documents on the SEDAR website atwww.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

Read the rest here:
Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada - InvestorIntel

Promising Steps Toward Retinal Cell Transplants to Fight Blindness – HealthDay News

By adminJanuary 22, 2021Stem Cell Treatment

TUESDAY, Jan. 19, 2021 (HealthDay News) -- A promising step toward using retinal cell transplants to treat blindness is reported in a new study.

Adult retinal stem cells from deceased human donors survived when they were transplanted into the eyes of non-human primates, according to the researchers.

The cells were taken from the retinal pigment epithelium (RPE). It is a layer of cells that supports and nourishes the retina, the light-sensitive tissue that lines the back of the eye. It helps maintain normal vision.

RPE dysfunction can result in disorders such as macular degeneration and can cause blindness, which affects about 200 million people worldwide.

"The results of this study suggest human adult donor RPE is safe to transplant, strengthening the argument for human clinical trials for treating retina disease," said co-lead investigator Timothy Blenkinsop. He's an assistant professor of cell, developmental and regenerative biology at the Icahn School of Medicine at Mount Sinai, in New York City.

For the study, his team transplanted cell-derived patches under the primates' maculas. The transplants remained stable and integrated for at least three months with no serious side effects, such as being attacked by the immune system or light sensitivity, according to the report published Jan. 14 in the journal Stem Cell Reports.

The stem cell-derived RPE assumed some of the function of the original RPE, and also supported a photoreceptor that helps with functions such as light and water absorption, the findings showed.

"We have demonstrated human cadaver donor-derived RPE at least partially replaces function in the macula of a non-human primate," Blenkinsop said in a Mount Sinai news release.

Results of animal studies, however, often differ in humans.

The study authors said RPE stem cell transplantation is a possible treatment for macular degeneration, but further research is needed to confirm that.

Future studies should assess whether such transplants can restore vision in people and diseased eyes in non-human primates, the researchers said.

More information

The U.S. National Eye Institute has more on age-related macular degeneration.

SOURCE: Mount Sinai Hospital, news release, Jan. 14, 2021

Read this article:
Promising Steps Toward Retinal Cell Transplants to Fight Blindness - HealthDay News

Trending News on Targeted Oncology, Week of January 22, 2021 – Targeted Oncology

By adminJanuary 22, 2021Stem Cell Treatment

This week in oncology news, the FDA granted Priority Review designation to 4 therapies. The Priority Review designations were across multiple malignancies and cancer-related conditions, including for patients with post-transplant complications, gastric/gastroesophageal junction and esophageal adenocarcinoma, as well as with squamous cell carcinoma of the anal canal.

In addition, the American Cancer Society released an update on the cancer mortality rate, and new data were reported from the 2021 Gastrointestinal Cancer Symposium.

FDA Grants Priority Review to Narsoplimab for Treatment of Post-Transplant Complications

The FDA has accepted a Biologics License Application for narsoplimab and granted it Priority Review for use as treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.

FDA Grants Priority Review to 1L Nivolumab Combination in Gastric/GEJ/Esophageal Cancers

The FDA has granted a Priority Review to the combination of nivolumab with fluoropyrimidine- and platinum-containing chemotherapy, which is a potential treatment option for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.

FDA Grants Priority Review to Adjuvant Nivolumab for Resected Esophageal/GEJ Cancer

The FDA accepted a supplemental Biologics License Application for nivolumab as adjuvant treatment of patients with resected esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiation therapy and granted it Priority Review.

Cancer Mortality Rate Declines as Advances in Cancer Treatment and Management Arise

Cancer mortality has been on a continuous decline since its peak in 1991, resulting in an overall reduction of 31% in the mortality rate and approximately 3.2 million fewer cancer deaths in the United States.

Trastuzumab Deruxtecan Brings HER2 Therapy to 3L HER2+ Advanced Gastric/GEJ Cancers

In an interview with Targeted Oncology, Yelena Y. Janjigian, MD, provided important highlights from the DESTINY-Gastric01 trial and explained the overall impact of the FDA approval of trastuzumab deruxtecan for oncologists treating patients with HER2-positive advanced gastric cancer or GEJ cancers.

Pembrolizumab Monotherapy May Play Role in Treatment-Naive HCC

Pembrolizumab monotherapy demonstrated durable antitumor activity and encouraging effects on survival in an evaluation of patients with previously untreated hepatocellular carcinoma.

Evaluating the Toxicity Profile of Parsaclisib in Mantle Cell Lymphoma

Amitkumar Mehta, MD, discusses the toxicity profile of parsaclisib in the phase 2 CITADEL-205 clinical trial of relapsed/refractory mantle cell lymphoma.

Finding the Optimal Dose of Regorafenib in Colorectal Cancer

John H. Strickler, MD, discusses dosing of regorafenib in patients with colorectal cancer.

Complications of Coagulopathy Caused by COVID-19 Puts Patients With Cancer at Risk

Subsequent observations related to the COVID-19 have led to the discovery cardiac manifestations, gastrointestinal complications, and hematological manifestations associated with this virus.

Read the rest here:
Trending News on Targeted Oncology, Week of January 22, 2021 - Targeted Oncology

Stem Cell Therapy Market Size, Growth Opportunities, Trends, Key Players and Forecast to 2027 – The Courier

By adminJanuary 22, 2021Stem Cell Treatment

Company Profile

New Jersey, United States,- Stem Cell Therapy Market Report gives a detailed analysis of the market. After a detailed examination of the current trends, the report shares the details around the factors fueling the markets momentum.

Forgiving an in-depth review of the market, the report showcases the factors that are affecting the markets overall growth. From network partners, production methods to revenue generating techniques, every detail is added in the report. In addition, the Stem Cell Therapy report has enclosed the data about the established players of the market.

Stem Cell Therapy report has a dedicated section that highlights the actions that can be appointed for global level expansion. The report is designed to guide through every step from planning till implementation.

The major players covered in the Stem Cell Therapy market are

Osiris Therapeutics Medipost Co. Ltd. Anterogen Co. Ltd. Pharmicell Co. Ltd. HolostemTerapieAvanzateSrl JCR Pharmaceuticals Co. Ltd. Nuvasive RTI Surgical Allosource

It is worth noting that the Stem Cell Therapy market report also gives a complete overview in terms of volume, market value, demand and supply. All these factors add up to become the market dynamics of the Stem Cell Therapy market. For leaping ahead of the competition and to make the most out of the emerging opportunities, it is essential to understand the market dynamics.

As per the Verified Market Reports experts, the Stem Cell Therapy market is going to balloon in terms of revenue and customer base. This conclusion was drawn out from the market indicators that are considered in the Stem Cell Therapy market report to form curated data. The crucial pieces of data are included in the form of tables, charts and graphs to give a visual representation of the complex and huge database.

What key insights does the Stem Cell Therapy market research provide?

Past and current revenue statistics of the Stem Cell Therapy market players analyzed at the regional level. Individual profiling of major stakeholders. Analysis of the Stem Cell Therapy market size on the basis of product type and end-use type. Accurate Stem Cell Therapy market forecast of volume in numbers and percentages. Demand prospect of individual segments covered in the Stem Cell Therapy report.

Segmentation of Stem Cell Therapy Market:

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

Stem Cell Therapy Market Report Scope

What queries are resolved by the Stem Cell Therapy market research?

1. What are the restraints slowing down the progress of Stem Cell Therapy market? 2. Why are the end consumers getting more inclined towards alternative Stem Cell Therapy market products? 3. How the Stem Cell Therapy market expected to shape in the next septennial? 4. What strategies are being appointed by the major players of the Stem Cell Therapy market to stay ahead of the competition? 5. What innovative technologies are being used by the established players of the Stem Cell Therapy market to stay ahead of the competition?

Why choose Verified Market Reports?

Smart dashboard to provide details about updated industry trends. Data collection from different network partners such as suppliers, vendors, service providers, for giving out a clear perspective of the Stem Cell Therapy market. Strict quality checking standards Data collection, triangulation, and validation. 24/7 at your service.

Visualize Stem Cell Therapy Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment and Key players of your market. Present your Market Report & findings with inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us: Verified Market Reports

Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information enriched research studies.

We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyse data on more than 25,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Our research spans over a multitude of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages etc. Having serviced many Fortune 2000 organizations, we bring a rich and reliable experience that covers all kinds of research needs.

Mr. Edwyne Fernandes

US: +1 (650)-781-4080 UK: +44 (753)-715-0008 APAC: +61 (488)-85-9400 US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketreports.com

Website: